Completion of Investment (Imperial Innov)

Date : 04/08/2009 @ 1:22PM
Source : UK Regulatory (RNS and others)
Stock : Imperial Innov (IVO)
Quote : 385.0  17.5 (4.76%) @ 11:35AM
<< BackQuote Chart

 



Completion of Investment (Imperial Innov)

 
TIDMIVO 
 
For Immediate release: 8 April 2009 
 
                        Imperial Innovations Group plc 
 
                   ("Imperial Innovations" or the "Company") 
 
          Completion of GBP2.5m investment in portfolio company Veryan 
 
Further to the announcement of 2 April 2009 concerning the Company's investment 
in Veryan Holdings Ltd, Imperial Innovations is pleased to confirm that this 
investment has now been completed. 
 
For further information please contact: 
 
Imperial Innovations 
 
Susan Searle, Chief Executive 
 
Diana Crisp, PR Manager 
 
Tel. +44 (0)20 7594 6589 
 
M:Communications 
 
Patrick d'Ancona or Ben Simons 
 
Tel. +44 (0)20 7153 1540 
 
J.P. Morgan Cazenove (NOMAD to Imperial Innovations) 
 
Steve Baldwin 
 
Tel. +44(0)20 7588 2828 
 
About Imperial Innovations 
 
Imperial Innovations is one of the UK's leading technology commercialisation 
and investment companies. Founded in 1986 and admitted to the AIM Market of the 
London Stock Exchange in 2006, Imperial Innovations' access to early stage 
technology and intellectual property is unparalleled. Imperial Innovations' 
integrated commercialisation approach encompasses the identification of ideas, 
the protection of intellectual property, the development and licensing of 
technology and the formation, incubation and funding, through investment, of 
technology businesses. 
 
Based at Imperial College London, Imperial Innovations' portfolio of equity 
holdings in more than 80 companies spans across its four core areas of 
Healthcare, Engineering, Energy & Environment and Software & IT. 
 
Companies in the portfolio include: Nexeon (lithium ion battery technology), 
Circassia (allergy therapeutics), Polytherics (drug development), Evo Electric 
(electric motor and generator solutions), Respivert (respiratory drug 
development), Quantasol (solar concentrators) and Inforsense (business 
analytics) 
 
Imperial Innovations has already realised significant value from its 
investments to date including from a recent trade sale in December 2008 when 
Thiakis Limited, a company in which Imperial Innovations had a 23.7% stake, was 
sold for up to GBP100 million to US-based Wyeth Pharmaceuticals. 
 
www.imperialinnovations.co.uk 
 
 
 
END 
 
<< Back


Imperial Innov Historical Chart Imperial Innov Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2009 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
34 site:2us 091124 18:48 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 )